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We have previously demonstrated that mutated DNA derived from the circulation can be
detected in urine and predominantly exists as DNA fragments <1 kb. To preferentially
isolate the trans-renal DNA from urine, we developed a method using carboxylated
beads to separate high-MW (1 kb or larger) from low-MW DNA in urine. A primer
set for 18s rRNA (generating a PCR product of 872 bp) was designed and optimized for
real-time PCR quantification of high-MW DNA templates. To evaluate the method, urine
samples from 5 volunteers with no known diseases and 36 patients with various colorec-
tal diseases were collected and tested. It was found that the average removal efficiency
of high-MW DNA from total urine DNA using carboxylated beads is 92.72% ± 1.42%.
Furthermore, compared with using total urine DNA, our method provides a greater
ability to detect mutated K-ras in the urine of colorectal cancer patients. The concur-
rence of K-ras mutations detected in disease tissue and the corresponding urine spec-
imen is significantly higher (P = 0.0015) when the samples were enriched in low-MW
DNA.
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Introduction
We1 and others2,3 have shown that short,
tumor-derived DNA can pass through the kid-
ney barrier and be excreted into urine. We have
also demonstrated previously that urine con-
tains DNA in two size categories: small (150
to 250 bp) cell-free, nucleosome-sized DNA
fragments [designated as low-molecular-weight
(MW) urine DNA] mostly from the circulation,
and large (1,000+ bp), cell-associated DNA
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from the urinary tract. Furthermore, we have
shown that the preferential isolation of low-
MW urine DNA by fractionation of total urine
DNA through agarose gel electrophoresis was
useful in enhancing the detection of circulating
mutated K-ras DNA.1 However, this agarose
gel fractionation method is very tedious and
time-consuming, so other possibilities for low-
MW DNA isolation from human urine were
explored.
Solid-phase carboxylated magnetic beads
(CMBs) have been used to purify nucleic acids
from other contaminants, and the size of the nu-
cleic acids that bind to CMBs has been shown
to vary with the binding conditions.4,5 In this
study a method to remove high-MW urine
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DNA by CMB was developed and evaluated
for its efficacy, and its applications were further
explored.
Materials and Methods
Study Subjects and Specimens
Participants were recruited from the Great
Lakes—New England Clinical Epidemiologi-
cal Center, which includes the University of
Michigan, Dana–Farber Harvard Cancer Cen-
ter, M.D. Anderson Medical Center, and the
University of Toronto. Cancer patients were
enrolled from surgical or oncologic services
(prior to initiation of chemo- or radiation ther-
apy or surgery). Most “healthy—no known
neoplasia” controls were subjects enrolled at
endoscopy suites, but had undergone a negative
colonoscopy. Patient samples were obtained un-
der IRB approvals.
Urine Collection and DNA Isolation
To freshly collected urine, 0.5 M EDTA,
pH 8.0, was added to a final concentration of
10 mM EDTA to inhibit possible nuclease ac-
tivity in the urine sample, and stored at −70◦C.
To isolate total urine DNA, the frozen urine
sample was thawed at room temperature, and
then placed immediately on ice prior to DNA
isolation. DNA was isolated from thawed urine
within an hour.
Urine samples were mixed with 1.5 vol-
umes of 6 M guanidine thiocyanate by inverting
8 times. 1 mL of resin (Wizard DNA Isolation
Kit, Promega, Madison, WI, USA) was added
into the urine lysate and incubated for 2 h
at room temperature with gentle mixing. The
resin–DNA complex was centrifuged, trans-
ferred to a minicolumn (provided in the kit),
and washed with a buffer provided by the man-
ufacturer, and the DNA was then eluted with
TE buffer. DNA from paraffin-embedded tis-
sue sections was isolated using the MasterPure
DNA Kit (Epicentre, Madison, WI, USA) ac-
cording to the manufacturer’s instructions.
Fractionation of High-MW (>1 kb) and
Low-MW (<1 kb) DNA by Carboxylated
Magnetic Beads
To fractionate high-MW (>1 kb) and low-
MW (<1 kb) DNA, total urine DNA (resus-
pended in TE buffer) was mixed with 5 M NaCl
and 20% polyethylene glycol 8000 (PEG) (AM-
RESCO Inc., Solon, OH, USA) to final con-
centrations of 0.3 M and 8% respectively (as
illustrated in Fig. 2A). The CMB suspension
(AgentCourt Bioscience Corporation, Beverly,
MA, USA) was washed and resuspended with
TE buffer prior to use. Ten µL of pre-washed
CMB suspension was added in the DNA mix
and incubated for 1–2 hours at room tem-
perature to allow the binding of high-MW
DNA to the beads. The beads were then re-
moved from the suspension by using a mag-
netic plate (AgentCourt). The low-MW DNA
that remained in the suspension was collected
by addition of 10 µL of pre-washed CMBs in
a solution of 1.2 M NaCl and 10% PEG. The
beads were then washed with 75% ethanol and
the DNA was eluted in TE buffer.
DNA Quantification by Real-Time
Polymerase Chain Reaction (PCR)
Total or high-MW DNA was quantified
by real-time PCR assays, performed using
the LightCycler PCR instrument (Roche Ap-
plied Science, Indianapolis, IN, USA) and
the LightCycler–Faststart DNA master SYBR
Green kit (Roche) according to the manu-
facturer’s specifications. The primer set used
to quantify total DNA is specific to the al-
bumin gene (forward, 5′-CCG TGG TCC
TGA ACC AGT TA-3′; reverse, 5′-GTC GCC
TGT TCA CCA AGG AT-3′) at an anneal-
ing temperature of 55◦C. The primer set
used to quantify the high-MW DNA is spe-
cific to the 18s rRNA gene (#872) (forward
primer: 5′-TCCAGCTCCAATAGCG-3′, re-
verse primer: 5′-GGCATCACAGACCTGTT-
3′) with an annealing temperature of 55◦C. Se-
rially diluted genomic DNA was included for
calibration in each assay.
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Restriction-Enriched Polymerase Chain
Reaction (RE–PCR) Detection of the
Codon 12 Mutation of the K-ras Gene
The RE–PCR assay, described previously,1
was used to distinguish wild-type and mutant K-
ras sequences in DNA isolated from urine or tis-
sue. Twenty cycles of hot-start PCR were per-
formed as follows. DNA, equivalent to 0.2 mL
of urine, with 1.5 mM MgCl2, 1× PCR buffer
(Qiagen, Valencia, CA, USA), 0.5 U Hot-Start
Taq (Qiagen), 200 µM dNTP, 0.1 µM primers:
L-Ext (5′ GCT CTT CGT GGT GTG GTG
TCC ATA TAA ACT TGT GGT AGT TGG
ACC T 3′) and R-Ext (5′ GCT CTT CGT
GGT GTG GTG TCC CGT CCA CAA AAT
GAT TCT GA 3′) were mixed and denatured
at 95◦C for 15 min, followed by 20 cycles of
94◦C 30 sec, 52◦C 30 sec, and 1 cycle of
72◦C for 5 min. The first 20 cycles of PCR
were used to amplify both wild-type and mu-
tated DNA, but only to introduce an artificial
BstNI site to the 5′ end of the amplified prod-
uct derived from wild-type DNA. After the first
round of PCR, the amplified products were di-
gested with BstNI (New England Biolab, Bev-
erly, MA, USA) to eliminate amplified products
derived from wild-type DNA. 1/20 of the di-
gested product was then subjected to a second
hot-start PCR with 1 µM of the primers L (5′
ACT GAA TAT AAA CTT GTG GTA GTT
GGA CCT 3′) and R-Bst (5′ GTC CAC AAA
ATG ATC CTG GAT TAG C 3′) under the
following conditions: 95◦C 15 min, 40 cycles of
94◦C 30 sec, and 56◦C 30 sec, followed by 1 cy-
cle of 72◦C 5 min. This second set of primers
introduced a BstNI site to the 3′ end of ampli-
fied product derived from both wild-type and
mutated templates serving as internal control
for the BstNI diagnostic digestion after the sec-
ond PCR. The amplified products (87 bp) of
the second PCR were digested to completion
with BstNI (as shown by disappearance of the
87-bp DNA fragment), and resolved through
polyacrylamide gels. The appearance of the 71-
bp DNA fragment after BstNI digestion is evi-
dence of the K-ras mutation. Each sample was
assayed 2–3 times. The samples were scored
as “positive” for mutated K-ras when the 71-
bp DNA fragments appeared after the second
BstNI digestion of the PCR products in at least
two of three repeated assays. As validation con-
trols, the standard reconstitution samples were
included in each assay.
Results and Discussion
Heterogeneity of Urine DNA among
Individuals
Before a method for the preferential isolation
of circulatory DNA in urine could be designed,
knowledge about urine DNA profiles in differ-
ent individuals needed to be augmented. The
urine of six different individuals (subjects A, B,
C, D, E, and F) was collected at three different
time points during a 24-hour period [after wak-
ing up (first caught), at 10 AM, and at 2 PM].
Half of the urine was subjected to total DNA
isolation and the DNA profiles of these samples
were analyzed, as shown in Figure 1A. Clearly,
there was considerable heterogeneity in the to-
tal amount of DNA present in each sample, as
well as in the ratio of high- to low-MW DNA
derived from the urine of the same individ-
ual at different time points and from the urine
of different individuals at similar time points.
The other half of the collected urine was cen-
trifuged at 2000 rpm for 10 min in order to
fractionate the supernatant and the cell debris
(pellet), and was then subjected to DNA isola-
tion. DNA derived from both fractions was then
analyzed in a polyacrylamide gel. As shown in
Figure 1B, both the supernatant and the cell
debris pellet from the urine of every individ-
ual contained both high- and low-MW DNA
as revealed by the ethidium bromide staining
after electrophoresis. It is clear that centrifu-
gation alone is not able to efficiently separate
high-MW DNA from low-MW DNA. This may
have been caused by the stickiness of the DNA
to the cell debris pellet.
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Figure 1. Heterogeneity of human urine. (A) Total urine DNA profile. Urine was collected
from six human subjects (A-F) at three different time points of the day: early AM (first-caught),
around 10 AM, and around 2 PM. Total urine DNA was isolated as previously described,
resolved in 9% polyacrylamide gels, and visualized by ethidium bromide staining under UV
transilluminator. (B) DNA profiles in the supernatant and cell debris–associated fractions.
Urine was collected, frozen, and thawed before centrifugation at 2000 rpm for 10 min. DNA
was isolated from the supernatant fraction (S) and cell pellet fraction (P), respectively, and
then analyzed in polyacrylamide gels as described in (A).
Removal of High-MW DNA by
Carboxylated Magnetic Beads
Solid-phase carboxylated magnetic beads
(CMBs) have been used to purify nucleic acids
from other contaminants, and the size of the nu-
cleic acids that bind to CMB has been shown to
vary with the binding conditions.4,5 To estab-
lish conditions in which CMBs (AgentCourt) se-
lectively bind to DNA ≥1 kb in size (reagent 1),
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and to develop a binding condition to bind the
DNA remaining in the supernatant (reagent 2)
following high-MW DNA removal, solutions
were prepared that ranged from 0.1 M–1.2 M
NaCl and 5%–12% polyethylene glycol (PEG).
The test DNA was a mixture of two DNA
molecular-weight markers, the 100-bp DNA
ladder (Invitrogen, Carlsbad, CA, USA) and
the 1-kb DNA ladder (Promega).
A procedure to remove high-MW DNA and
preferentially isolate low-MW DNA was estab-
lished as outlined in Figure 2A and described in
the Materials and Methods section. In brief: the
tested DNA was mixed with beads in reagent
1 (0.3 M NaCl, 8% PEG) for 1 or 2 h. The
DNA–bead complex was then sedimented us-
ing a magnetic plate (AgentCourt), and the su-
pernatant was transferred to reagent 2 to collect
the remaining DNA. To estimate the binding
efficiency, the fractions were resolved in a 1.0%
agarose gel and stained with ethidium bromide.
As shown in Figure 2B, after 2 hours’ incuba-
tion at room temperature, almost no detectable
high-MW DNA was left unbound in the so-
lution (lane 8). There was very limited, if any,
small DNA (less than 1 kb) detected in the high-
MW DNA fraction (lane 9). However, in the 1-
hour incubation group, some high-MW DNA
remained in the supernatant (lane 5). Thus, a 2-
hour incubation period was used for the subse-
quent experiments. Almost all the bound DNA
was eluted in water, as no DNA was detected
in the beads fraction (lanes 4 and 7), suggesting
that the elution of DNA from the beads was
efficient.
To quantitatively measure the efficacy of
high-MW DNA removal using this method, a
real-time polymerase chain reaction (PCR) as-
say was devised. A primer set 18s#872 (forward
primer: 5′-TCCAGCTCCAATAGCG-3′; re-
verse primer: 5′-GGCATCACAGACCTGTT-
3′) generating a PCR product of 872 bp from
the 18s ribosome gene was designed and opti-
mized for real-time PCR quantification using
the LightCycler (Roche Diagnostics, Indi-
anapolis, IN, USA). The linearity of the ampli-
fication of serial dilutions of the human control
DNA (Roche) by the 18s#872 primers is shown
in Figure 2C.
To evaluate the efficacy of high-MW DNA
removal from total urine DNA by CMBs, urine
from 5 volunteers with no known disease was
collected and subjected to total DNA isolation.
Half of the total urine DNA from each indi-
vidual was then subjected to high- and low-
MW DNA fractionation using the developed
method. The amount of high-MW DNA of
each fraction (total, high and low) was then
quantified by real-time PCR using the 18s#872
primer set. Since this primer set only amplifies
high-MW DNA, it should effectively determine
the efficacy of high-MW DNA removal. In the
five sets of fractionated urine DNA samples,
the average efficacy of high-MW DNA removal
ranged from 88.1% to 96%, with an average
of 92.72% ± 1.42%, as shown in Figure 2D.
Thus, CMB was shown to be able to effectively
remove high-MW DNA from total urine DNA.
Removal of High-MW DNA by
Carboxylated Magnetic Beads Enhanced
the Detection of Mutated K-ras DNA in
Urine of Patients with Colorectal
Diseases
After the validity of the method was es-
tablished, this method was applied to the de-
tection of a colorectal cancer (CRC)–related
biomarker, the K-ras codon 12 mutations.
Thirty-six blinded urine specimens, collected
from subjects with various colorectal diseases,
were subjected to total urine DNA isolation,
and then to the CMB procedure to obtain the
low-MW DNA fraction. The matched paraffin-
embedded disease tissue sections (if available)
were subjected to DNA isolation using a Mas-
terPure DNA kit (Epicentre). To detect K-ras
codon 12 mutations, restriction endonuclease-
enriched polymerase chain reaction (RE-PCR)
was performed as previously described1 on to-
tal and low-MW urine DNA and tissue DNA
(if available). Patient information such as diag-
nosis, age, and gender were revealed after the
assays were performed.
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Figure 2. Preferential isolation of low-MW urine DNA from total urine DNA using carboxylated magnetic
beads (CMBs). (A) Schematic outline of the isolation procedure. (B) Estimation of the efficiency of CMB
binding to high- and low-MW DNA. DNA markers (a mix of 1-kb and 100-bp DNA markers, as mentioned
in the text) were subjected to the procedure outlined in panel A for the separation of high-and low-MW
DNA fractions using a 1-hour (1 h) or 2-hour (2 h) incubation time with binding reagent 1. After separation,
the total input DNA (T), the beads (B), the low-MW DNA fraction (L), and the high-MW DNA fraction
(H) were resolved in a 1% agarose gel, stained with ethidium bromide, and photographed under the UV
transilluminator. (C) Real-time PCR amplification of the 18s primer set # 872. Serial dilutions of human
genomic DNA (as indicated) were subjected to real-time PCR amplification with the 18s primer #872, as
described in text, using LightCycler FastStart DNA Master SYBR Green kit (Roche Diagnostics) according to
the manufacturer’s specifications (except for the concentration of MgCl2, which was 3 mM). The time and
temperature in each step of the real-time PCR were 94◦C (10 sec), 55◦C (5 sec), and 72◦C (20 sec) for
45 cycles. The linear regression fit was plotted. (D) Efficacy of high-MW DNA removal. Urine from five
volunteers was collected and subjected to total urine DNA isolation as described previously.1 Half of total
urine DNA was fractionated into high-and low-MW DNA fractions as outlined in panel A. The amount of
high-MW DNA in each fraction was quantified by real-time PCR using 18s primers #872 as described in
panel C. The percent of high-MW DNA removal was calculated as noted. (E) Detection of mutated K-ras DNA
in low-MW urine DNA. Total and low-MW urine DNA were prepared as described in text and subjected
to the RE-PCR assay for mutated K-ras DNA. The photos shown represent the difference in the outcome of
RE-PCR between total and low-MW urine DNA from the same individuals listed in Table 1.
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In brief: DNA derived from either 200 µL
urine or 1/10 of a tissue section was used in
each assay. The PCR product from the RE-
PCR assay is 87 bp, and the appearance of a
71-bp fragment after the second BstNI diges-
tion is evidence of mutated K-ras DNA in the
DNA sample. The detection limit of the assay is
15 copies of the mutant K-ras per 100 ng of wild-
type DNA per reaction (data not shown). As val-
idation controls, DNA prepared from sources
known to have either mutant (human adeno-
carcinoma SW480 cells) or wild-type (human
hepatoblastoma HepG2 cells) K-ras sequences
was subjected to PCR. As expected, and shown
in Figure 2E, DNA prepared from HepG2 cells
contained no detectable levels of mutant K-
ras (no appearance of the 71-bp fragment af-
ter the second BstNI digestion), whereas DNA
prepared from SW480 cells contained mutant
K-ras sequences (the 71-bp fragment was de-
tected after the second BstNI digestion). For
each urine sample that contained detectable
mutant K-ras DNA, the presence of the mutant
K-ras sequence was more evident when low-
MW DNA was used in the assay as compared
to the total urine DNA, as demonstrated by
the six examples in Figure 2E. The data are
summarized in Table 1.
The participants in this blind study either
had colorectal cancer (n = 16), adenomatous
polyps (n = 12), hyperplastic polyps (n = 2), or
no known neoplasia (n = 7). For the colorec-
tal cancer group, 43.8% of total urine DNA
samples were positive for the K-ras mutations,
whereas 87.5% of samples were positive when
the low-MW DNA fraction was used as the
substrate for the assay. For the group with ade-
nomatous polyps, 16.7% of urine samples were
positive for the K-ras mutations when total urine
DNA was used, whereas 75% of urine samples
were positive for the K-ras mutations if the low-
MW DNA fraction was used. When the detec-
tion of K-ras mutations using total urine DNA
and low-MW DNA were compared using the
Fisher’s exact test, the P-value was 0.0233 for
the colorectal cancer group and 0.0123 for the
adenomatous polyps group, suggesting there
is a significant difference between the num-
ber of positive total urine DNA samples and
the number of positive low-MW DNA sam-
ples. Statistical analysis was not performed for
the hyperplastic polyps and no known neopla-
sia groups because of small sample sizes, and
there was no tissue DNA available for the latter
group. Furthermore, the concurrence of K-ras
mutations detected in disease tissue (colorectal
cancer, adenomatous polyps, and hyperplastic
polyps) and the corresponding urine specimen
is also higher when the low-MW urine DNA
fraction was used for the assays (86%, 18/21)
as compared to total urine DNA (38%, 8/21),
with a P-value of 0.0015 as analyzed by the
chi-square test. Of interest, this 86% concur-
rence is similar to our previous findings using
a smaller sample size in which the detection of
mutated K-ras DNA was found to be positive
using total urine DNA or DNA isolated from
cell-free urine. The latter option of using DNA
isolated from cell-free urine was only utilized if
the mutated K-ras DNA was not detected using
the total urine DNA. This strongly indicates
that the low-MW urine DNA fraction is better
than total urine DNA for detection of K-ras mu-
tations in urine of colorectal disease patients.
One possible contributor to this discrepancy
in assay results between total urine DNA and
low-MW urine DNA from the same individ-
ual could be due to a better ratio of the target
DNA to the nonspecific DNA. The removal
of high-MW DNA from the total urine DNA
would result in a better ratio of K-ras-mutated
DNA (presumably from the circulation) to wild-
type DNA (from the circulation and sloughed
off urinary tract cells). This is particularly im-
portant in light of the nature of the RE-PCR
K-ras mutation assay. The detection sensitivity
of the target mutant DNA sequences could be
reduced as a result of interference from an ex-
cessive amount of wild-type DNA in the PCR.
This would reduce the amplification efficiency
of the DNA sequence of interest.
In summary, this study clearly demonstrates
that (1) there is significant heterogeneity among
the urine DNA profiles of different individuals
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and among the urine DNA profiles at differ-
ent times of urine collection; (2) CMBs can
be used to preferentially isolate low-MW urine
DNA from total urine DNA; and (3) the low-
MW urine DNA fraction rather than total urine
DNA should be used to increase assay sensitiv-
ity for detection of circulation-derived, cancer-
related DNA biomarkers in urine for cancer
detection, monitoring, and/or prognosis.
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